Sartorius Stedim生物技术报告说,由于对细胞和基因治疗的需求增加,生物药物解决方案在2025年前九个月出现强劲增长。 Sartorius Stedim Biotech reported strong 2025 first-nine-month growth in biopharma solutions due to rising cell and gene therapy demand.

Sartorius Stedim Biotech报称,2025年头九个月的财务结果未经审计,表明收入和业务业绩继续增长,尽管具体数字在发布时没有详细说明。 Sartorius Stedim Biotech reported unaudited financial results for the first nine months of 2025, showing continued growth in revenue and operational performance, though specific figures were not detailed in the release. 该公司强调,由于对细胞和基因治疗制造的投资增加,其生物制药解决方案部门的需求强劲。 The company emphasized strong demand across its biopharmaceutical solutions segment, driven by increased investments in cell and gene therapy manufacturing. 没有提供指导意见或前瞻性说明。 No guidance or forward-looking statements were provided.